Quote:

---

The information was there, but it was mixed up and somewhat unclear/confusing, which is nearly identical to how NP’s interviews go: he makes a few random comments, contradicts one comment with the other, and mixes terms instead of sticking to one term to describe an item (adverse event vs serious adverse event or interim analysis vs safety review). The BLA refusal PR is also a great example: the PR had 3 different titles that were each a paragraph long and the main body rambled on with mentioned of HIV and COVId. If I as a 5+ year investor in CYDY have to constantly reread the PRs and go the the board for clarification, then there’s an issue.

---

This post, or at least the most salient points made in this post, needs to be forwarded to Dr. Scott Kelly. I don't suggest this with malicious intent -- only to alert him to the fact that this cannot continue.